Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.
Interested in receiving a copy of the Contemporary Pediatrics journal every month?
Want to stay up to date with pediatric news? Subscribe to the Contemporary Pediatrics e-newsletter to receive emailed updates regarding new data, pediatric clinical trials, puzzler cases, FDA news, and much more.
Thank you for visiting the Contemporary Pediatrics® website. Take a look at some of our top stories from the week (Monday, February 24, to Friday, February 28, 2025), and click on each link to read and watch anything you may have missed.
According to multiple national reports, a child who was not vaccinated has died amid a measles outbreak occurring in Texas. This marks the first measles-related death in the U.S. since 2015. As of February 26, 2025, 124 cases have been reported across 9 counties. Tina Tan, MD, FIDSA, FPIDS, FAAP, editor-in-chief of Contemporary Pediatrics, discusses the outbreak, the role of vaccine misinformation, and the importance of public health efforts in preventing vaccine-preventable diseases.
Stallergenes Greer has announced the U.S. launch of Palforzia for children aged 1 through 3 years with a confirmed peanut allergy diagnosis. Palforzia remains the first and only FDA-approved oral immunotherapy designed to reduce allergic reactions, including anaphylaxis, after accidental peanut exposure. The launch follows phase 3 POSEIDON study data, highlighting the benefits of early intervention with oral immunotherapy.
On February 26, 2025, the FDA accepted the supplemental new drug application (sNDA) for roflumilast cream 0.05% (Zoryve) to treat atopic dermatitis in children aged 2 to 5 years. The decision follows positive data from the INTEGUMENT-PED phase 3 trial, demonstrating significant improvements in disease severity and itch reduction. The FDA has set a potential approval date for October 13, 2025.
In December 2024, the American Academy of Pediatrics (AAP) introduced updates to the critical congenital heart disease (CCHD) screening algorithm to enhance efficiency and accuracy in newborn screenings. The refinements aim to reduce misinterpretation and improve sensitivity, ensuring more consistent implementation across hospitals.
The FDA has approved the intranasal influenza vaccine (FluMist) for at-home administration by parents for children aged 2 to 17 years and self-administration for individuals aged 18 to 49 years. This marks the first vaccine approved for at-home use. The article explores the regulatory oversight of vaccines by the FDA and ACIP, as well as the importance of maintaining evidence-based immunization schedules to prevent disease outbreaks.
Welcome to this Contemporary Pediatrics poll. Take a look at the following case below.
A 6-day-old male with history of waxing and waning urticarial rash presents to the general pediatrician’s office for evaluation. The parents describe the rash as red, raised skin lesions that become flat and congregate, lasting several hours to days, resolving without leaving marks and then appearing in new areas. The rash began shortly after birth, and it does not seem to bother the patient. The parents deny any other concerns, including vomiting, fever, joint swelling, oral ulcers, or irritability. The patient is breastfeeding well and has normal urination and bowel movements.
On review of the nursery notes, it appears that at 9-hours of life the patient developed a rash that started as small, blanching, erythematous, circular macules on the legs; gradually increasing in size and number; becoming raised and coalescing to large, diffuse patches on the legs, back, chest, face, and soles that resolved within several hours. The patient was born to a 30-year-old gravida one mother at 40-weeks gestation via spontaneous vaginal delivery. The parents are without consanguinity or family history of autoimmune or inflammatory diseases. The pregnancy was complicated by maternal hypothyroidism and group B Streptococcus positive status, with the mother adequately treated with levothyroxine and intrapartum antibiotics.
